292 related articles for article (PubMed ID: 12839285)
21. Acute intermittent porphyria: psychosis as the only clinical manifestation.
Ellencweig N; Schoenfeld N; Zemishlany Z
Isr J Psychiatry Relat Sci; 2006; 43(1):52-6. PubMed ID: 16910386
[TBL] [Abstract][Full Text] [Related]
22. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
Barreda-Sánchez M; Buendía-Martínez J; Glover-López G; Carazo-Díaz C; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Rodriguez-Peña L; Serrano-Antón AT; Gil-Ferrer R; Martínez-Romero MDC; Carbonell-Meseguer P; Guillén-Navarro E
Orphanet J Rare Dis; 2019 Feb; 14(1):59. PubMed ID: 30808393
[TBL] [Abstract][Full Text] [Related]
23. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
[TBL] [Abstract][Full Text] [Related]
24. Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
Lissing M; Wester A; Vassiliou D; Floderus Y; Harper P; Sardh E; Wahlin S
J Inherit Metab Dis; 2023 Nov; 46(6):1186-1194. PubMed ID: 37650859
[TBL] [Abstract][Full Text] [Related]
25. A quantitative assay of porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) in the urine of one hundred normal Punjabis. A spectrophotometric study.
Verma ML; Handa F; Sidhu KS
Indian J Dermatol; 1983 Oct; 28(4):133-43. PubMed ID: 6671701
[No Abstract] [Full Text] [Related]
26. Effects of diabetes mellitus on patients with acute intermittent porphyria.
Andersson C; Bylesjö I; Lithner F
J Intern Med; 1999 Feb; 245(2):193-7. PubMed ID: 10081522
[TBL] [Abstract][Full Text] [Related]
27. Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy.
Carichon M; Pallet N; Schmitt C; Lefebvre T; Gouya L; Talbi N; Deybach JC; Beaune P; Vasos P; Puy H; Bertho G
Anal Chem; 2014 Feb; 86(4):2166-74. PubMed ID: 24437734
[TBL] [Abstract][Full Text] [Related]
28. Determination of 5-aminolaevulinic acid dehydratase activity in erythrocytes and porphobilinogen in urine by micellar electrokinetic capillary chromatography.
Luo JL; Deka J; Lim CK
J Chromatogr A; 1996 Jan; 722(1-2):353-7. PubMed ID: 9019304
[TBL] [Abstract][Full Text] [Related]
29. A family with acute intermittent porphyria.
Billoo AG; Lone SW
J Coll Physicians Surg Pak; 2008 May; 18(5):316-8. PubMed ID: 18541093
[TBL] [Abstract][Full Text] [Related]
30. Effects of clonidine in a primed rat model of acute hepatic porphyria.
Goerz G; Bolsen K; Böhrer H; Fritsch C; Kalka K; Rominger KL
Arzneimittelforschung; 1997 Jun; 47(6):731-3. PubMed ID: 9239451
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Sardh E; Rejkjaer L; Andersson DE; Harper P
Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
[TBL] [Abstract][Full Text] [Related]
32. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study.
Bylesjö I; Wikberg A; Andersson C
Scand J Clin Lab Invest; 2009; 69(5):612-8. PubMed ID: 19401933
[TBL] [Abstract][Full Text] [Related]
33. [Reference values of urinary delta-aminolevulinic acid in children].
Grisler R; Ferrari L; Ronco G; Rusconi R; Biella C; Carnelli V
Pediatr Med Chir; 1983; 5(3):87-9. PubMed ID: 6647070
[TBL] [Abstract][Full Text] [Related]
34. [A case of acute intermittent porphyria].
Nielsen KR
Ugeskr Laeger; 1997 Feb; 159(7):960-1. PubMed ID: 9054089
[TBL] [Abstract][Full Text] [Related]
35. Acute porphyrias in the Argentinean population: a review.
Parera VE; De Siervi A; Varela L; Rossetti MV; Batlle AM
Cell Mol Biol (Noisy-le-grand); 2003 Jun; 49(4):493-500. PubMed ID: 12899439
[TBL] [Abstract][Full Text] [Related]
36. Neurological complications of acute intermittent porphyria.
Kuo HC; Huang CC; Chu CC; Lee MJ; Chuang WL; Wu CL; Wu T; Ning HC; Liu CY
Eur Neurol; 2011; 66(5):247-52. PubMed ID: 21986212
[TBL] [Abstract][Full Text] [Related]
37. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Johansson A; Möller C; Fogh J; Harper P
Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
[TBL] [Abstract][Full Text] [Related]
38. Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study in northern Norway.
Storjord E; Dahl JA; Landsem A; Ludviksen JK; Karlsen MB; Karlsen BO; Brekke OL
Mol Genet Metab; 2019 Nov; 128(3):254-270. PubMed ID: 30583995
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation for acute intermittent porphyria: a viable treatment?
Dar FS; Asai K; Haque AR; Cherian T; Rela M; Heaton N
Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):93-6. PubMed ID: 20133237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
